Hyprei Pharmaceuticals (09989.HK) posted a profit forecast to grow 420.7% year-on-year to 495.72% in the range of RMB0.642 billion to 0.735 billion yuan; net profit after non-recurring losses of RMB 0.308 billion to 0.4 billion yuan, an increase of RMB286.28 billion year-on-year. 96% to 403.2%.

The Company explained that the global market share increased further due to the continued growth in market sales of its main product Enopectin sodium preparations in Europe, the United States, China, etc., during the period, as well as the combined effects of good price system maintenance, improved cost control efficiency, and lower raw material costs. The rate increased compared to the same period last year after excluding the impact of prices collected in the Chinese market.